A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study

A. K. L. Reyners, L. de Munck, F. L. G. Erdkamp, W. M. Smit, K. Hoekman, R. I. Lalisang, H. de Graaf, A. N. M. Wymenga, M. Polee, H. Hollema, M. A. T. M. van Vugt, M. Schaapveld, P. H. B. Willemse

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2896-2902
JournalAnnals of Oncology
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 2012

Keywords

  • carboplatin
  • celecoxib
  • docetaxel
  • epithelial ovarian cancer
  • first-line chemotherapy
  • randomized phase II study

Cite this

Reyners, A. K. L., de Munck, L., Erdkamp, F. L. G., Smit, W. M., Hoekman, K., Lalisang, R. I., de Graaf, H., Wymenga, A. N. M., Polee, M., Hollema, H., van Vugt, M. A. T. M., Schaapveld, M., & Willemse, P. H. B. (2012). A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology, 23(11), 2896-2902. https://doi.org/10.1093/annonc/mds107